TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01354379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
Study: NCT02194738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV
Study: NCT01354379

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone IN
Description: The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone IN
Description: The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
Study: NCT02905747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Exercise Therapy
Description: physiotherapy intervention with Medical exercise therapy (MET) during 3 months
Study: NCT00706862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin
Description: Oral, 1.5 grams twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice per day
Study: NCT03150693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, SC
Study: NCT02194738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT03150693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study: NCT02194738

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT03150693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated L-Asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated L-Asparaginase
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT, IV, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study: NCT02194738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT03150693

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01680003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepar-P

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Hepar-P
Study: NCT03937843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.
Study: NCT02714426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-inspired treatment
Description: Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
Study: NCT04278768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
Study: NCT00883545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Woman endoscopist
Description: This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
Study: NCT02959541

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Study: NCT02943330

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
Study: NCT02543866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation
Study: NCT02622581

Intervention type: OTHER
Intervention: data collection
Description: Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.

Intervention type: OTHER
Intervention: data collection
Description: Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
Study: NCT02818829

Intervention type: OTHER
Intervention: Collection of biological samples
Description: Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
Study: NCT02622581

Intervention type: OTHER
Intervention: data collection
Description: Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
Study: NCT03441971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE PV1
Description: Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
Study: NCT04409457

Intervention type: OTHER
Group type: OTHER
Intervention: fasting state
Description: 16 hours of fasting

Intervention type: OTHER
Group type: OTHER
Intervention: fasting state
Description: 16 hours of fasting

Intervention type: OTHER
Group type: OTHER
Intervention: fed state
Description: fed a standardized meal

Intervention type: OTHER
Group type: OTHER
Intervention: fed state
Description: fed a standardized meal

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging
Description: neuroimaging with computational modeling

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging
Description: neuroimaging with computational modeling
Study: NCT01750242

Intervention type: DEVICE
Intervention: Medtronic DBS system
Description: Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
Study: NCT02209389

Intervention type: DEVICE
Intervention: MRI
Description: For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).

Intervention type: DEVICE
Intervention: MRI
Description: For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
Study: NCT03628560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Step-Wise Normocapnia desaturation sequence
Description: Blood carbon dioxide controlled at normal value (normocapnia).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Slope Normocapnia desaturation sequence
Description: Blood carbon dioxide controlled at normal value (normocapnia).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Step-Wise Hypocapnia desaturation sequence
Description: Blood carbon dioxide controlled at lower than normal value (hypocapnia).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct Slope Hypocapnia desaturation sequence
Description: Blood carbon dioxide controlled at lower than normal value (hypocapnia).
Study: NCT02702869

Intervention type: PROCEDURE
Intervention: cleft lip repair

Intervention type: PROCEDURE
Intervention: cleft lip repair

Intervention type: PROCEDURE
Intervention: cleft lip repair

Intervention type: PROCEDURE
Intervention: cleft lip repair
Study: NCT03641768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetapir
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetapir
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
Study: NCT02702869

Intervention type: PROCEDURE
Intervention: cleft palate repair

Intervention type: PROCEDURE
Intervention: cleft palate repair

Intervention type: PROCEDURE
Intervention: cleft palate repair

Intervention type: PROCEDURE
Intervention: oronasal fistula repair

Intervention type: PROCEDURE
Intervention: oronasal fistula repair

Intervention type: PROCEDURE
Intervention: oronasal fistula repair

Intervention type: PROCEDURE
Intervention: pharyngoplasty

Intervention type: PROCEDURE
Intervention: pharyngoplasty

Intervention type: PROCEDURE
Intervention: pharyngoplasty

Intervention type: PROCEDURE
Intervention: gingivoperiosteoplasty

Intervention type: PROCEDURE
Intervention: gingivoperiosteoplasty

Intervention type: PROCEDURE
Intervention: gingivoperiosteoplasty

Intervention type: PROCEDURE
Intervention: gingivoperiosteoplasty

Intervention type: PROCEDURE
Intervention: LeFort-1 maxillary repositioning

Intervention type: PROCEDURE
Intervention: LeFort-1 maxillary repositioning

Intervention type: PROCEDURE
Intervention: LeFort-1 maxillary repositioning

Intervention type: PROCEDURE
Intervention: LeFort-1 maxillary repositioning
Study: NCT03641768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetapir
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radioligand 18F-AV-1451
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radioligand 18F-AV-1451
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radioligand 18F-AV-1451
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radioligand 18F-AV-1451
Description: At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
Study: NCT00664339

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flu Vaccine
Description: Single dose of Flu vaccine by year (1)

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional medical therapy for heart failure
Description: According with the international guidelines
Study: NCT05319899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
Study: NCT03481166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education on breastfeeding pain
Description: A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
Study: NCT01557777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: QD
Study: NCT03536780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab and Gemcitabine
Description: * Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
Study: NCT02350413

Intervention type: OTHER
Intervention: The Endometriosis Health Profile EPH-30
Description: Self-reported questionnaires
Study: NCT04463693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Description: Insertion of the contraceptive implant at an alternative insertion site located over the scapula
Study: NCT01747408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Albumin
Description: 25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day
Study: NCT00559429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 50mg/m2 IV on day 1 and day 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV on day 1 and day 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV on day 1 and day 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
Study: NCT04467229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus group
Description: 5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.